Next Article in Journal
Synthesis and Biological Activity Evaluation of Novel 5-Methyl-7-Phenyl-3H-Thiazolo[4,5-b]Pyridin-2-Ones
Previous Article in Journal / Special Issue
Phytochemistry and Evidence-Based Traditional Uses of the Genus Achillea L.: An Update (2011–2021)
Communication

Compatibility of Different Formulations in Pentravan® and Pentravan® Plus for Transdermal Drug Delivery

1
Fagron BV, Fascinatio Boulevard 350, 3065 WB Rotterdam, The Netherlands
2
Fagron US, 2400 Pilot Knob Rd. #200, St. Paul, MN 55120, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Helen D. Skaltsa
Sci. Pharm. 2021, 89(4), 51; https://doi.org/10.3390/scipharm89040051 (registering DOI)
Received: 25 October 2021 / Revised: 18 November 2021 / Accepted: 22 November 2021 / Published: 23 November 2021
(This article belongs to the Special Issue Feature Papers in Scientia Pharmaceutica)
The potential therapeutic benefit of transdermal delivery systems for some active pharmaceutical ingredients (APIs) has been well-established for decades within the scientific community. However, together with the clinical efficacy, there is the need for an evaluation of the stability of such APIs in bases with known transdermal capabilities, which is necessary to provide the compounding pharmacist with confidence when providing transdermal products. In this study, the stability of danazol, metformin HCl, and resveratrol as individual ingredients, as well as metformin HCl, resveratrol, and Vitamin D3 in combinations at bracketed high and low concentrations, were evaluated over a period of 6 months, using a ready-to-use transdermal vehicle for compounding pharmacies (Pentravan® or Pentravan® Plus). The five formulations tested (F1: Danazol 50 mg/g + MiodesinTM 85 mg/g in Pentravan®, F2: Metformin HCl 200 mg/g in Pentravan®, F3: Resveratrol 200 mg/g in Pentravan®, F4: Metformin HCl 100 mg/g + Resveratrol 100 mg/g + Vitamin D3 5000 IU in Pentravan®, and F5: Metformin HCl 200 mg/g + Resveratrol 200 mg/g + Vitamin D3 5000 IU in Pentravan® Plus) presented a beyond-use date of at least 6 months, presenting high convenience for the compounding pharmacies. View Full-Text
Keywords: transdermals; hormones; compounding pharmacy transdermals; hormones; compounding pharmacy
Show Figures

Figure 1

MDPI and ACS Style

Polonini, H.; Taylor, S.; Zander, C. Compatibility of Different Formulations in Pentravan® and Pentravan® Plus for Transdermal Drug Delivery. Sci. Pharm. 2021, 89, 51. https://doi.org/10.3390/scipharm89040051

AMA Style

Polonini H, Taylor S, Zander C. Compatibility of Different Formulations in Pentravan® and Pentravan® Plus for Transdermal Drug Delivery. Scientia Pharmaceutica. 2021; 89(4):51. https://doi.org/10.3390/scipharm89040051

Chicago/Turabian Style

Polonini, Hudson, Sarah Taylor, and Clark Zander. 2021. "Compatibility of Different Formulations in Pentravan® and Pentravan® Plus for Transdermal Drug Delivery" Scientia Pharmaceutica 89, no. 4: 51. https://doi.org/10.3390/scipharm89040051

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop